MSC-delivered High-Affinity Variants of soluble PD1 lead to tumour regression
Mohr, A.; Zwacka, R. M.; Gokcen, S.; Chu, T.; Blair, P.; Krajewska, N.; Brooke, G. N.; Rushworth, S.
Show abstract
Immune checkpoint therapies aim to restore anti-tumour immunity by blocking inhibitory signals that suppress T-cell activation. The most effective current strategies use humanised antibodies targeting PD1 or its ligand PDL1. However, due to their large size, antibodies often exhibit limited tissue diffusion, resulting in poor penetration into solid tumours. To address this challenge, we developed a novel checkpoint inhibitor approach that uses mesenchymal stromal cells (MSCs) to deliver a high-affinity, soluble PD1 receptor (sPD1HAC). We found that sPD1HAC produced as an IgG1-Fc fusion protein provided functional expression in MSCs. The sPD1HAC-IgG1-Fc fusion protein showed strong and specific binding to PDL1 and could outcompete recombinant PD1 and anti-PDL1 antibodies, including the clinically approved durvalumab. Although the sPD1HAC variant was designed to block human PD1-PDL1 signalling, it also bound murine PDL1 and blocked the binding of mouse-specific PD1 antibodies as well as recombinant murine PD1 protein. Accordingly, we found significant anti-tumour activity of intravenously administered MSCs.PD1HAC in an aggressive B16-F10 cancer model. This cell-based immune checkpoint approach offers a potential therapeutic option for targeting stroma-rich, treatment-resistant tumours.
Matching journals
The top 20 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- CAR-T Engager Proteins Optimize Anti-CD19 CAR-T Cell Therapies for Lymphoma 95%
- CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts 94%
- CD20 expression regulates CD37 levels in B-cell lymphoma: implications for immunotherapies. 94%
Similar papers in this journal
- Blockade of Interleukin-6 (IL-6) Signaling in Dedifferentiated Liposarcoma (DDLPS) Decreases Mouse Double Minute 2 (MDM2) Oncogenicity via Alternative Splicing 95%
- The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer 94%
- A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy 94%
Similar papers in this journal
- Interferon-γ Increases Sensitivity to Chemotherapy and Provides Immunotherapy Targets in Models of Metastatic Castration-Resistant Prostate Cancer 94%
- GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior 94%
- Knocking out alpha-synuclein in melanoma cells downregulates L1CAM and decreases motility 94%
Similar papers in this journal
- An antibody-tumor necrosis factor fusion protein that synergizes with oxaliplatin for treatment of colorectal cancer 94%
- Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and CD155/TIGIT Pathway 94%
- Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer 94%
Similar papers in this journal
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 93%
- PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer 93%
- The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration. 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.